Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rinvecalinase alfa
- Development stage
- Phase 3
- Lead developer
- DiaMedica Therapeutics
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) being developed by DiaMedica Therapeutics for the treatment of acute ischemic stroke (AIS) and preeclampsia. KLK1 is a serine protease that plays a crucial role in physiological regulation by increasing the production of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factors. In the context of AIS, DM199 acts as a bradykinin-producing enzyme that aims to improve clinical outcomes by enhancing collateral circulation to the ischemic penumbra, stimulating angiogenesis, and promoting cellular repair mechanisms. It is currently being evaluated in the Phase 2/3 ReMEDy2 trial for patients with moderate stroke severity who present within 24 hours of symptom onset and are not candidates for mechanical thrombectomy.
- Brand names
- DM199DM-199DM 199
- Other names
- recombinant human tissue kallikrein-1rhKLK1rhKLK-1rhKLK 1
02
Targets
Bradykinin B2 receptorKNG1 (High-molecular-weight kininogen)KLK1 (Kallikrein-1)
Beyond the preview
Go deeper on rinvecalinase alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rinvecalinase alfa.